Neuphoria Therapeutics (NEUP) Total Liabilities (2020 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Total Liabilities of $5.4 million for Q1 2026, up 14.19% year-over-year from $4.7 million in Q1 2025, and down 21.92% quarter-over-quarter from $6.9 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Total Liabilities (2020 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Total Liabilities for 7 consecutive years, with $5.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 14.19% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $5.4 million (up 14.19% YoY), while the FY2025 annual figure was $9.6 million, down 5.63% from the prior year.
- Total Liabilities retreated to $5.4 million in Q1 2026 per NEUP's latest filing, from $6.9 million in the prior quarter.
- Across five years, Total Liabilities topped out at $14.8 million in Q3 2025 and bottomed at $4.4 million in Q4 2024.
- Historically, Total Liabilities has averaged $7.4 million across 5 years, with a median of $6.3 million in 2022.
- On a YoY basis, Total Liabilities climbed as much as 153.7% in 2025 and fell as far as 5.63% in 2025.
- Neuphoria Therapeutics' Total Liabilities stood at $6.0 million in 2022, then rose by 9.52% to $6.6 million in 2023, then tumbled by 32.9% to $4.4 million in 2024, then surged by 56.04% to $6.9 million in 2025, then slipped by 21.92% to $5.4 million in 2026.
- Business Quant data shows NEUP's Total Liabilities at $5.4 million in Q1 2026, $6.9 million in Q4 2025, and $14.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - | 5.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.39 Mn |
| Dec 31, 2025 | 6.90 Mn |
| Sep 30, 2025 | 14.83 Mn |
| Jun 30, 2025 | 9.59 Mn |
| Mar 31, 2025 | 4.72 Mn |
| Dec 31, 2024 | 4.42 Mn |
| Sep 30, 2024 | 5.85 Mn |
| Jun 30, 2024 | 10.16 Mn |
| Jun 30, 2023 | 6.59 Mn |
| Jun 30, 2022 | 6.01 Mn |
| Jun 30, 2021 | 5.13 Mn |
| Jun 30, 2020 | 715,830.75 |